¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"partial antigen"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antigen recognition
    Ç׿øÀνÄ
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü»óÈ£ÀÛ¿ë
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-presenting cell
    Ç׿øÁ¦½Ã¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • avidin-antigen conjugate
    ¾ÆºñµòÇ׿øÁ¢ÇÕü
  • capsid antigen
    ĸ½ÃµåÇ׿ø
  • capsular antigen
    ÇǸ·Ç׿ø
  • common antigen
    °øÅëÇ׿ø
  • complete antigen
    ¿ÏÀüÇ׿ø
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen diffusion constant
    Ç׿øÈ®»ê»ó¼ö
  • antigen excess zone
    Ç׿ø°úÀ×±¸¿ª
  • antigen-antibody complex
    Ç׿øÇ×üº¹ÇÕü
  • antigen-antibody interaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿øÇ×ü¹ÝÀÀ
  • antigen-binding site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-combining site
    Ç׿ø°áÇÕºÎÀ§
  • antigen-presenting cell
    Ç׿øÀü´Þ¼¼Æ÷
  • antigen-reactive cell
    Ç׿ø¹ÝÀÀ¼¼Æ÷
  • antigen-recognition site
    Ç׿øÀÎÁöºÎÀ§
  • antigen-recognizing cell
    Ç׿øÀÎÁö¼¼Æ÷
  • avidin-antigen conjugate
    ¾ÆºñµòÇ׿øÁ¢ÇÕü
  • capsid antigen
    ĸ½ÃµåÇ׿ø
  • capsular antigen
    ÇǸ·Ç׿ø
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • HBs antigen
    BÇü °£¿°¹ÙÀÌ·¯½º Ç¥¸éÇ׿ø
  • HBsAg => hepatitis B surface antigen
    B Çü °£¿° s Ç׿ø
  • HDAg => hepatitis D antigen
    D Çü °£¿°Ç׿ø
  • HLA => human leukocyte antigen
    ÀÎüÁ¶Á÷ÀûÇÕÇ׿ø<ÀÎü¹éÇ÷±¸Ç׿ø>
  • HLA antigen
    HLAÇ׿ø.
  • HLA= human leukocyte antigen ; hist ocompatibility antigens ; tran splan tation antigens
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, ÀιéÇ÷±¸Ç׿ø.
  • HLA= human leukocyte antigen ; histocompatibility antigens ; transplantation anti
    HLA<Á¶Á÷ÀûÇÕÀ̽Ä>Ç׿ø, »ç¶÷¹éÇ÷±¸Ç׿ø.
  • Hepatitis B core antigen(HBc Ag)
    BÇü °£¿°ÇÙ½ÉÇ׿ø
  • I antigen
    I Ç׿ø
  • I region-associated antigen
    Ir¿¬°üÇ׿ø
  • Ia antigen
    IaÇ׿ø
  • Jk antigen/antibody
    JkÇ׿ø/Ç×ü
  • K antigen
    K Ç׿ø.
  • K antigen
    K Ç׿ø.
  • K antigen
    K Ç׿ø.
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • partial hospital
    ºÎºÐº´¿ø
  • partial hospitalization
    ºÎºÐÀÔ¿ø
  • partial hypertrophy (pyloric stenosis)
    ºÎºÐ°ú´ÙÇü¼º (³¯¹®ÇùÂøÁõ)
  • partial immunity
    ºÎºÐ¸é¿ª(Ý»ÝÂØóæ¹).
  • partial inversion (aorticopulmonary transposition)
    ºÎºÐÀÚ¸®¹Ù²Þ (´ëµ¿¸ÆÇãÆÄµ¿¸ÆÀÚ
  • partial laminectomy
    ºÎºÐÃß±ÃÀýÁ¦¼ú.
  • partial laryngectomy
    ÈĵκκÐÀýÁ¦¼ú
  • partial lipodystrophy
  • partial maxillectomy
    »ó¾Ç°ñ ºÎºÐÀýÁ¦¼ú
  • partial myectomy
    ºÎºÐ±ÙÀýÁ¦(¼ú)
  • partial nephrectomy
    ºÎºÐ½ÅÀýÁ¦¼ú(Ý»ÝÂãìôîð¶âú).
  • partial obstruction
    ºÎºÐÀû Æó»ö
  • partial occlusion
    ºÎºÐ°¡¸²
  • partial order
    ¹Ý¼ø¼­(Úââ÷ßí).
  • partial organ duplication (bifurcated ureter)
    ºÎºÐ±â°üÁߺ¹ (¿ä°ü°¥¸²Áõ)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • particulate antigen
    ÀÔÀÚ Ç׿ø(Ø£í­ù÷ê«)
  • penton antigen
    ÆæÅæ Ç׿ø(ù÷ê«)
  • protective antigen
    º¸È£ Ç׿ø(ÜÁûÞù÷ê«)
  • R antigen
    R Ç׿ø(ù÷ê«)
  • S antigen
    S Ç׿ø(ù÷ê«)
  • SH-antigen
    SH-Ç׿ø(ù÷ê«)
  • soluble antigen
    °¡¿ëÇ׿ø(ʦéÁù÷ê«)
  • surface antigen
    Ç¥¸éÇ׿ø (øúØüù÷ê«)
  • t antigen
    t Ç׿ø(ù÷ê«)
  • T antigen
    T Ç׿ø(ù÷ê«)
  • Thy-1-antigen
    Thy-1-Ç׿ø(ù÷ê«)
  • tissue polypeptide antigen
    Á¶Á÷(ðÚòÄ)Æú¸®ÆéŸÀ̵å Ç׿ø (ù÷ê«)
  • tolerogenic antigen
    ³»¼º»ý¼º Ç׿ø (Ò±àõßæà÷ù÷ê«)
  • transplantation antigen
    ÀÌ½Ä Ç׿ø(ì¹ãÕù÷ê«)
  • tumor antigen
    Á¾¾çÇ׿ø(ðþåËù÷ê«)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
HTA heterophil transplantation antigen; human thymocyte antigen; hydroxytryptamine; hypophysiotropic are...
LA lactic acid; large amount; laser angioplasty; late abortion; late antigen; latex agglutination; left...
LFA left femoral artery; left frontal craniotomy; left fronto-anterior [fetal position]; leukocyte funct...
MSA major serologic antigen; male-specific antigen; mannitol salt agar; Medical Services Administration;...
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
PR Partial Response
PTT Partial Thromboplastine Time
PAPVC Partial anomalous pulmonary venous connection
PEFV Partial expiratory flow-volume
P.H. Partial hepatectomy
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antigen presentation
    Ç׿ø Á¦°ø, Ç׿ø Àü´Þ, Ç׿ø Á¦½Ã
  • antigen processing
    Ç׿ø ó¸®
    Ç׿øÀÌ Ç׿ø Á¦½Ã ¼¼Æ÷¿¡ ÀÇÇÏ¿© Æ÷ÃËµÇ°í ³ª¼­ B ¼¼Æ÷, T ¼¼Æ÷¿¡ Ç׿øÀÌ Á¦½ÃµÇ±â±îÁöÀÇ °úÁ¤À» ¸»ÇÑ´Ù. ÀÌ °úÁ¤¿¡´Â Ç׿øÀÇ Å½½Ä, Ç׿øÀÇ ´ÜÆíÈ­ ȤÀº Ç׿ø °áÁ¤±â±îÁöÀÇ ºÐÇØ 󸮰¡ Æ÷ÇԵȴÙ.
  • antigen receptor
    Ç׿ø ¼ö¿ëü
  • antigen recognition site
    Ç׿ø ½Äº°ºÎ
  • antigen shift
    Ç׿ø ´ëº¯ÀÌ
  • antigen unit
    Ç׿ø ´ÜÀ§
  • antigen-antibody reaction
    Ç׿ø-Ç×ü ¹ÝÀÀ
  • carcinoembryonic antigen assay
    ¾Ï ¹è¾Æ¼º Ç׿ø ÃøÁ¤, ¾Ï¼º ¹è¾Æ¼º Ç׿ø ÃøÁ¤
  • class I human leukocyte antigen
    Á¦ 1±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • class II human leukocyte antigen
    Á¦ 2±Þ ÀÎü ¹éÇ÷±¸ Ç׿ø
  • dander antigen
    Àμ³ Ç׿ø
    ÇǺÎÀÇ Ç¥¸éÀ¸·ÎºÎÅÍ ²÷ÀÓ¾øÀÌ »êÆ÷µÇ°í ÀÖ´Â ¹°ÁúÀÇ È¥ÇÕ¹°. ¹Ú¸®µÈ »óÇÇ ¼¼¹Î, ÅÐÀÇ ´ÜÆí, ÇǺÎÀÇ Áö¹æ µîÀÌ Æ÷ÇԵǴµ¥ ƯÈ÷ Àμ³ÀÌ Áß¿äÇÏ´Ù. ¾ÆÅäÇǰ¡ ÀÖ´Â »ç¶÷¿¡¼­´Â Áï½ÃÇü °ú¹ÎÁõÀÇ ¿øÀÎÀÌ µÇ´Â ¼ö°¡ ÀÖ´Ù.
  • determinant antigen
    Ç׿ø °áÁ¤±º, °áÁ¤ Ç׿ø
    ¸é¿ªÇÐÀû ƯÀ̼ºÀ» °áÁ¤Çϴ ƯÁ¤ÀÇ È­ÇÐÀûÀÎ ºÐÀÚ±º.
  • diego antigen
    µð¿¡°í Ç׿ø
  • differentiation antigen
    ºÐÈ­ Ç׿ø
    ¼¼Æ÷°¡ ºÐÈ­ÇØ °¡´Âµ¥ À־ Ç¥ÇöµÇ´Â ¼¼Æ÷¸· »óÀÇ Ç׿ø. T ¼¼Æ÷¿¡¼­´Â B ¼¼Æ÷·ÎºÎÅÍ ±¸º°ÇÏ´Â ºÐÈ­ Ç׿øÀº mouse »çÀÌ¿¡¼­ ¼¼Æ÷¸¦ Åõ¿©ÇÏ¿© ¸¸µé¾îÁø µ¿Á¾ Ç×Ç÷û¿¡ ÀÇÇÏ¿© °ËÃâµÇ´Â Ç׿ø
  • DR antigen
    DR Ç׿ø
    HLA-D ¿µ¿ª À¯ÀüÀÚÀÇ Áö¹è¸¦ ¹Þ´Â Ç׿øÀ̸ç, ÁÖ·Î B ¼¼Æ÷ ¹× macro
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
epilepsy, complex partial Epileptic seizures that are episodic changes in behaviour in which an individual loses conscious contact with the environment. The onset of such seizures involves any of a variety of auras: deja-vu, an unusual smell, a sudden intense emotional feeling, a sensory illusion such as micropsia (objects growing smaller) or macropsia (objects growing larger), or other sensory hallucination. There may be a cessation of activity with some minor motor activity such as lip smacking, walking aimlessly, or other automatisms. The seizures may also be accompanied by the unconscious performance of highly skilled activities such as driving a car. When the seizure ends, the individual is amnesic for events that took place during the seizure and may take minutes or hours to recover fully to consciousness.
(12 Dec 1998)
epilepsy, partial Epileptic seizures that originate at a specific location or focal point in the cortex of the brain and either remain localised or may generalise. These seizures occur without the loss of consciousness of the individual. The specific clinical symptoms depend on the area of the cortex involved.
(12 Dec 1998)
fixed partial denture A restoration of one or more missing teeth which cannot be readily removed by the patient or dentist; it is permanently attached to natural teeth or roots which furnish the primary support to the appliance.
Synonym: bridge.
(05 Mar 2000)
law of partial pressures Each gas in a mixture of gases exerts a pressure proportionate to the percentage of the gas and independent of the presence of the other gases present.
Synonym: law of partial pressures.
(05 Mar 2000)
acetone-insoluble antigen A diphosphatidyl glycerol that is found in the membrane of Treponema pallidum and is the antigen detected by the Wasserman test for syphilis.
(18 Nov 1997)
allogeneic antigen Genetic variations of the same antigens within a given species.
(05 Mar 2000)
antigen Virus coded cell surface antigens that appear soon after the infection of a cell by virus, but before virus replication has begun.
See: early gene.
(18 Nov 1997)
antigen-antibody complex The complex formed by the binding of antigen and antibody molecules. The deposition of large antigen-antibody complexes leading to tissue damage causes immune complex diseases. If the antigen is polyvalent the complex may be insoluble.
Immune complexes activate complement through the classical pathway.
See: glomerulonephritis, Arthus reaction, type III hypersensitivity.
(12 Dec 1998)
antigen-antibody reaction The phenomenon, occurring in vitro or in vivo, of antibody combining with antigen of the type that stimulated the formation of the antibody, thereby resulting in agglutination, precipitation, complement fixation, greater susceptibility to ingestion and destruction by phagocytes, or neutralization of exotoxin.
See: skin test.
(05 Mar 2000)
antigen-binding site <immunology> In immune network theory, an idiotope, an antigenic site of an antibody that is responsible for that antibody binding to an antigenic determinant (epitope).
Also used of the site on a ligand molecule to which a cell surface receptor binds.
(18 Nov 1997)
antigen-combining site See: paratope.
(05 Mar 2000)
antigen excess In a precipitation test, the presence of uncombined antigen above that required to combine with all of the antibody; precipitation may be inhibited because the presence of excess antigen gives rise to soluble antigen-antibody complexes, in vivo the resultant antigen-antibody interaction in such an antigen excess may give rise to immune complexes, which have a potential to induce cellular damage; such injury underlies the pathologic changes seen in certain immune complex diseases.
(05 Mar 2000)
antigen interferon <cytokine> Interferon elaborated by T lymphocytes in response to either specific antigen or mitogenic stimulation.
This type II interferon can be produced by recombinant DNA technology and is similar to the interferon secreted by lymphocytes and has antiviral and antineoplastic activity.
Synonym: antigen interferon, immune interferon.
Pharmacological action: antineoplastic agent, antiviral agents.
(20 Sep 2002)
antigen p150,95 A major adhesion-associated heterodimer molecule expressed by human monocytes, granulocytes, nk cells, and some lymphocytes. The alpha subunit is the CD11c antigen (also called leu-m5), a surface antigen expressed on some myeloid cells. The beta subunit is the CD18 antigen (antigens, CD18). The p150,95 antigen has been shown to play an important role in cell-cell and cell-substrate adhesive interactions.
(12 Dec 1998)
antigen presentation A cell that carries on its surface antigen bound to MCH Class I or Class II molecules and presents the antigen in this context to T-cells. Includes macrophages, endothelium, dendritic cells and Langerhans cells of the skin.
See: MHC restriction, histocompatibility antigens.
(18 Nov 1997)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á